Skip to main content

ML28897

NCT02091141

ML28897

Associated Conditions

Cancer

Principal Investigator

Sponsor

Genentech, Inc.

Many cancers contain molecular abnormalities (cells show biological and genetic changes in the laboratory) that cause or contribute to their ability to grow and spread. By blocking the effects of these abnormalities, the growth of cancer may be stopped or slowed down. Many new cancer drugs work in this way. Because they block the effects of specific molecular abnormalities within the cancer, they are known as 'targeted' agents.As more such targets are identified, and more drugs are found to work against them, more patients are now having molecular tests done on their tumor tissue ('molecular profiling'), in order to identify potential molecular targets for treatment.

This study is currently enrolling.


Interested in participating?

Fill out the information below and we will reach out to you within two business days with more information on qualifications for this trial and how to participate.